Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 25, 2022 08:00 ET | Source: Immutep Limited

Immutep Quarterly Activities Report

Media Release Clinical development strategy for efti to prioritise non-small cell lung cancer (NSCLC), as well as advance head & neck squamous cell cancer (HNSCC) and metastatic breast cancer...
October 05, 2022 08:00 ET | Source: Immutep Limited

Immutep Announces Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting

SYDNEY, AUSTRALIA, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel immunotherapies...
October 04, 2022 08:00 ET | Source: Immutep Limited

Immutep Receives FDA Fast Track Designation for LAG-3 Therapeutic Eftilagimod Alpha for First Line Non-Small Cell Lung Cancer

Fast Track designation has been granted by the US FDA for efti in combination with pembrolizumab in 1st line non-small cell lung cancerBased on the encouraging Phase II clinical data for PD-L1...
September 26, 2022 08:00 ET | Source: Immutep Limited

Immutep to Participate in Two Upcoming Investor Conferences

SYDNEY, AUSTRALIA, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel immunotherapies...
September 23, 2022 08:00 ET | Source: Immutep Limited

Immutep Receives A$2.7 million R&D Tax Incentive from French Government

SYDNEY, AUSTRALIA, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy...
September 14, 2022 08:00 ET | Source: Immutep Limited

Immutep Clinical Development Update for its First-in-Class LAG-3 Antigen Presenting Cell Activator Candidate Eftilagimod Alpha

Encouraging Phase II data supports broad therapeutic potential of eftilagimod alpha in non-small cell lung cancer (NSCLC), head & neck squamous cell cancer (HNSCC) and metastatic breast cancer...
September 13, 2022 08:00 ET | Source: Immutep Limited

Immutep Appoints LAG-3 Pioneer, Frédéric Triebel to Board

SYDNEY, AUSTRALIA, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunotherapy...
September 06, 2022 08:00 ET | Source: Immutep Limited

Immutep Announces Investigator-Initiated Phase II Trial Evaluating LAG-3 Candidate Eftilagimod Alpha (Efti) in Soft Tissue Sarcoma

Expansion of the efti clinical development pipeline with a new Phase II settingEfti Phase II trial awarded €1.5M (~A$2.2M) in funding as part of the Polish Medical Research Agency program funded by...
August 30, 2022 08:00 ET | Source: Immutep Limited

Immutep Granted Japanese Patent for Eftilagimod Alpha, a Soluble Lag-3 Protein, in Combination with a PD-1 Pathway Inhibitor

SYDNEY, AUSTRALIA, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy...
August 01, 2022 08:00 ET | Source: Immutep Limited

Immutep Reports New Positive Interim Data from its Phase II Study of LAG-3 Candidate, Eftilagimod Alpha, in 2nd Line PD-X Refractory NSCLC

Encouraging efficacy results continue for patients with 2nd line PD-X refractory non-small cell lung cancer (NSCLC)Patients in this 2nd line setting had confirmed disease progression on anti-PD-1 /...